Crude aqueous extracts of Pluchea indica (L.) Less. inhibit proliferation and migration of cancer cells through induction of p53-dependent cell death
© Cho et al.; licensee BioMed Central Ltd. 2012
Received: 29 February 2012
Accepted: 30 November 2012
Published: 26 December 2012
Pluchea indica (L.) Less. (Asteraceae) is a perennial shrub plant with anti-inflammatory and antioxidant medicinal properties. However, the anti-cancer properties of its aqueous extracts have not been studied. The aim of this study was to investigate the anti-proliferation, anti-migration, and pro-apoptotic properties of crude aqueous extracts of P. indica leaf and root on human malignant glioma cancer cells and human cervical cancer cells, and the underlying molecular mechanism.
GBM8401 human glioma cells and HeLa cervical carcinoma cells were treated with various concentrations of crude aqueous extracts of P. indica leaf and root and cancer cell proliferation and viability were measured by cell growth curves, trypan blue exclusions, and the tetrazolium reduction assay. Effects of the crude aqueous extracts on focus formation, migration, and apoptosis of cancer cells were studied as well. The molecular mechanism that contributed to the anti-cancer activities of crude aqueous extracts of P. indica root was also examined using Western blotting analysis.
Crude aqueous extracts of P. indica leaf and root suppressed proliferation, viability, and migration of GBM8401 and HeLa cells. Treatment with crude aqueous extracts of P. indica leaf and root for 48 hours resulted in a significant 75% and 70% inhibition on proliferation and viability of GBM8401 and HeLa cancer cells, respectively. Crude aqueous extracts of P. indica root inhibited focus formation and promoted apoptosis of HeLa cells. It was found that phosphorylated-p53 and p21 were induced in GBM8401 and HeLa cells treated with crude aqueous extracts of P. indica root. Expression of phosphorylated-AKT was decreased in HeLa cells treated with crude aqueous extracts of P. indica root.
The in vitro anti-cancer effects of crude aqueous extracts of P. indica leaf and root indicate that it has sufficient potential to warrant further examination and development as a new anti-cancer agent.
KeywordsPluchea indica (L.) Less Crude aqueous extracts Cancer p53 p21 Cell growth arrest Apoptosis
Cancer is a prevalent medical problem with high mortality and wide epidemiology [1, 2]. It is a complex disease caused by numerous factors ranging from external environmental chemicals to hereditary genetics. Current treatment of cancer can be categorized into three groups: surgery, chemotherapy, and radiation therapy [3–5]. Surgical removal of tumor and cancerous growth can effectively treat 50% of cancer but cannot eliminate all cancer cells, which results in high recurrence rate . Chemotherapy and radiation therapy have the potential of removing all cancer cells but both lack the specificity to limit their damaging effect on cancer cells, thus harming normal body cells in the process and causing countless side-effects. Many chemotherapy chemicals target proliferating and high-metabolic cells, prominent characteristics of cancer cell and other fast-dividing cells, such as those of the integumentary system. The focal point of cancer research is still the search for effective and specific anti-cancer treatments .
The use of complementary and alternative therapies for cancer patients have grown in developed countries [6, 7]. A recent study estimated the overall prevalence for the use of herbal products to be 13% to 63% among cancer patients . A systematic review found that hypnosis, imagery, support groups, acupuncture, and healing touch seemed promising in relieving cancer pain in the short term; however, no formal recommendation can be made because of a paucity of rigorous randomized controlled trials . In a study on the use of complementary and alternative medicine (CAM) by breast cancer survivors in Ontario, Canada, the investigators found that 66.7% of the respondents in a randomized survey reported using CAM . The study concluded that CAM use is common among Canadian breast cancer survivors and that many are discussing CAM therapy options with their physicians . A meta-analysis of randomized trials for combined Astragalus-based herbs and platinum-based chemotherapy, as compared to platinum-based chemotherapy alone, for advanced non-small-cell lung cancer found that Astragalus-based herbal medicine may increase effectiveness of platinum-based chemotherapy; however, rigorous controlled trials are required to confirm these results . Thus, herbal medicine is emerging to play an important role in cancer treatment and survivor therapies.
Pluchea indica (Asteraceae) is a perennial shrub plant indigenous to many Asian countries . Anti-inflammatory properties were found in the methanolic fraction of the chloroform extract of P. indica root . The methanolic extract of P. indica root was found to possess the ability to neutralize viper venom and counter venom-induced lethality and hemorrhagic activity . Significant anti-ulcer and anti-tuberculosis activities were found in the methanol fraction of P. indica root and leaf extracts, respectively [14, 15].
This is the first study to demonstrate the in vitro anti-cancer property of P. indica aqueous extracts in the inhibition of cancer cell proliferation, focus formation, and migration. It was demonstrated that crude aqueous extracts of P. indica root effectively inhibited cancer cell proliferation, focus formation, and migration at low concentrations (100–300 μg/ml). Additionally, the underlying mechanism of anti-cancer activities may be attributed to the induction of critical tumor suppressor molecules, phosphorylated-p53 and p21, and decreased expression of an important survival signaling molecule, phosphorylated-AKT, in GBM8401 and HeLa cancer cells treated with crude aqueous extracts of P. indica root.
Human brain malignant glioma cell line GBM8401, and human cervical carcinoma cell line HeLa were used. GBM8401 was cultured in RPMI1640 (Invitrogen). HeLa was cultured in Dulbecco’s modified Eagle’s medium (DMEM). Both RPMI1640 and DMEM were made into complete medium with 10% cosmic calf serum (CCS; Hyclone), 200 mM L-glutamine (Invitrogen), 1% Penicillin (10000 units/ml)/Streptomycin (10000 units/ml) (Hyclone), 1X non-essential amino acids (NEAA; Invitrogen), 1 mM sodium pyruvate (Invitrogen). Cells were incubated at 37°C, in a humidified incubator with 5% CO2.
Preparation of Pluchea indica crude aqueous extracts
Live plant material of P. indica was collected from the Yanchiao campus of National Kaohsiung Normal University, Kaohsiung, Taiwan. The plant material was authenticated and prepared as root and leaf dry powder by Professor L J Liao. The extraction of crude aqueous extracts of P. indica leaf or root was prepared by the method of Li et al. . Briefly, 25 g of leaf or root powder were extracted three times in 200 ml of ddH2O (75°C-80°C) on a shaker. The resultant aqueous solution, which was filtered through 0.45-μm filters, was further concentrated by quickly frozen at −40°C and dried for 48 h using a freeze dryer (Savant Refrigerated vapor Trap, RV T41404, USA) to give a yield of 2.2 g crude leaf extracts (12.5%) and 1.3 g of crude root extracts (9.9%), respectively. The soluble aqueous extracts were dissolved in ddH2O to obtain stock solutions of P. indica leaf or root aqueous extract. Different desired concentrations of crude aqueous extracts were prepared by reconstitution with ddH2O and used in this study.
Preliminary phytochemical screening of Pluchea indica crude aqueous extracts
The P. indica dry crude extract was evaluated for total phenol and flavonoids contents using Folin-Ciocalteu reagent and the aluminum chloride colorimetric method and was calculated as gallic acid equivalents in mg/g of extract and catechin equivalents in mg/g of extract, respectively, according to methods described previously with minor modifications . Proanthocyanidins content was determined using the vanillin assay and expressed as catechin equivalents in mg/g of extract as described by Butler et al. . All assays were carried out in triplicate.
Determination of lipid peroxidation
Lipid peroxidation was measured in HeLa cells using the thiobarbituric acid (TBA) assay for malondialdehyde and normalized to total protein . Briefly, cell pellets were mixed with 0.3% deaerated thiobarbituric acid solution in 3.9% (w/v) trichloroacetic acid and incubated at 95–100°C for 20 min. After cooling, the reaction mixtures were centrifuged at 10,000 rpm for 10 min. The supernatants were then loaded in 96-well plates and determined at an absorbance of 532nm/600nm. The MDA contents were calculated based on A532-A600 with the extinction coefficient of 155 mM-1 cm-1.
Cell proliferation and viability assays
Trypan blue exclusions and the tetrazolium (3-(4,5-dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium; MTS) reduction assay were used to monitor the proliferation and viability of cancer cells upon exposure to different concentrations of aqueous extracts for different incubation periods. For the MTS assay, CellTiter 96 Aqueous One Solution Cell Proliferation Assay Kit (Promega, USA) was used by following manufacturer’s protocol. Briefly, 2 × 103 cells/well was seeded in 96-well plates. Following a 24-hour incubation, P. indica leaf or root aqueous extract at 0, 100, 500, and 1000 μg/ml concentrations was added and incubated for 72 hours. After the 72-hour incubation, the medium was removed, 100 μl of medium with 20 μl of MTS solution was added, and the cells were incubated for 3 hours. Absorbance was read at 490 nm with an ELISA Reader (Micro Quant, BIO-TEK, USA) and analyzed using the KC4 3.3 Rev 10 program (BIO-TEK instruments Inc., USA). Trypan blue dye exclusion was used to assess the viability of cancer cells grown under different conditions as described above. Growth curves, each covering a total of 6 days of culturing, were constructed from which the effects of P. indica aqueous extract on population doubling time and saturation density were determined.
Focus formation assay
One hundred cells were seeded in 60-mm plates and incubated at 37°C, 5% CO2 for 24 hours. The plates were prepared in triplicates. Following a 24-hour incubation, various concentrations of P. indica root aqueous extract were added. After 10 days, colonies were stained with crystal violet and counted.
In vitro “ scratch” wound closure assay
In vitro wound closure assay was performed as described previously . In brief, HeLa cells with 90% confluence were wounded by scraping across the cell monolayer with a pipette tip. After washing with PBS, cells were incubated in the media supplemented with aqueous extracts of P. indica root at 0, 250, and 500 μg/ml concentrations, respectively. “Scratch” wound closure of the scratched surface was observed and photographed at 0-, 24-, 48-, and 72-hour time intervals.
Apoptosis assay and flow cytometry analysis
Determination of apoptosis was conducted following manufacturer’s protocol by staining with FITC Annexin V Apoptosis Detection Kit I (BD Pharmingen, BD Biosciences, USA). Briefly, cells were plated in 100-mm culture dishes and allowed to grow to 70-80% confluence. They were treated with appropriate concentrations of aqueous extract and incubated for 2 days. The cells (1 × 105cells/100 μl were collected and 5 μl of FITC Annexin V and 5 μl of propidium iodide (PI) were added. Cells were then incubated in the dark at room temperature. After 15 min, 400 μl of 1 × binding buffer was added to the cells. Flow cytometry analysis was conducted using BD LSR II Flow Cytometer (BD). Flow cytometry data were analyzed using BD FACSDiva software (BD).
Western blot analysis
After treatment with P. indica aqueous extracts, cells were lysed with T-PER protein extraction reagent (Pierce), and 20 μg protein was used for immunoblotting analysis. Immunoblotting proteins were eluted by boiling for 5 min in a 1 × SDS sample buffer containing 5% (v/v) 2-mercaptoethanol. Proteins were resolved in a 12% SDS-PAGE and transferred to nitrocellulose membranes. The nitrocellulose membranes were immunoblotted with specific antibodies against p21 (Santa Cruz Biotechnology), phosphorylated-p53 (pS15) (Cell Signaling Technology), AKT (Cell Signaling Technology), phosphorylated-AKT (Cell Signaling Technology), Cleaved Caspase-3 (Asp175) (5A1E) Rabbit mAb (Cell Signaling Technology), α-tubulin (NeoMarkers), or β-actin (SIGMA), respectively. For visualization of immunoreactive bands, ECL+ reagents (Amersham) followed by chemiluminescence were used. Control and experimental groups were generated from the same blot.
Data are presented as mean ± standard deviations (SD) of three independent experiments and statistical significance was determined using Independent Student’s t-test and the SPSS 12.0 software (SPSS Inc., USA). A significant difference was considered if P < 0.05.
Phytochemical compounds of Pluchea indica root aqueous extract.
Percentage in extract
78.9±0.6 mg GAE/g DW
40.4±0.3 mg CE/g DW
4.248±0.068 mg CE/g DW
Membrane lipid oxidation
Crude aqueous extracts of P. indica leaf and root suppress cancer cell growth
Crude aqueous extracts of P. indica leaf and root decrease proliferation and viability of cancer cells
Crude aqueous extracts of P. indica root inhibits cancer cell focus formation
Crude aqueous extracts of P. indica leaf and root represses cancer cell migration
P. indica root aqueous extracts induce apoptosis in HeLa cervical carcinoma cells
P. indica root aqueous extracts suppress cancer cell proliferation and migration through the phosphorylated-p53 and p21 pathways
This study examined the cell growth arrest, anti-proliferation, anti-migration, and pro-apoptosis properties of Pluchea indica leaf and root crude aqueous extracts in human brain malignant glioma cell line GBM8401, and human cervical carcinoma cell line HeLa. The underlying inhibitory mechanism of P. indica leaf and root crude aqueous extract was also investigated. It was detected that membrane lipid oxidation level in HeLa cells increased after treatment with P. indica crude aqueous extract. The data showed that P. indica leaf and root crude aqueous extracts were effective in suppressing the proliferation and migration of GBM8401 and HeLa cells. It was found that P. indica root crude aqueous extract inhibited focus formation of GBM8401 and HeLa cells, and promoted apoptosis in HeLa cells. The data indicated that phosphorylated-p53 and p21 were induced in P. indica root crude aqueous extract-treated GBM8401 and HeLa cells, and that phosphorylated-AKT was decreased in HeLa cells treated with P. indica root crude aqueous extract.
The medicinal properties of P. indica extracts have been studied previously. The methanol fraction of P. indica root extract was found to possess antioxidant activity . The methanolic fraction of a chloroform extract of P. indica root was found to have anti-inflammatory activity . Beta-sitosterol and stigmasterol isolated from P. indica root methanol extract was found to be able to neutralize viper and cobra venom and antagonize cobra venom-induced lethality, cardiotoxicity, neurotoxicity, and respiratory changes . In contrast to previous studies, this is the first study to examine the effect of crude aqueous extracts of P. indica leaf and root on cancer cells. Tannins, saponins, flavonoids, phenols, and proanthocyanidins were detected in crude aqueous extracts of P. indica leaf and root, which showed that P. indica has reasonable anti-cancer potential because total phenolics, flavonoids, and tannins were shown to inhibit ATP-binding cassette transports in cancer cells , flavonoid intake was found to associate with a significant reduction in the risk of gastric cancer in women , saponins from Radix astragali were found to suppress colon cancer cell carcinogenic activity by reducing vascular endothelial growth factor , and proanthocyanidins from grape seeds inhibited pancreatic cancer cell growth and induced apoptosis .
Research into the anti-cancer potential of herbal extracts have been growing and expanding [6, 25]. The compound, n-butylidenephthalide, isolated from the chloroform extract of Angelica siensis was found to upregulate the expression of p21 and p27 and increase apoptosis-associated proteins in DBTRG-05MG and RG2 cells and suppress the growth of subcutaneous rat and human brain tumors . Nexrutine, a Phellodendron amurense bark methanol extract, was found to inhibit prostate cancer cell proliferation through modulation of AKT and cAMP-responsive element binding protein (CREB)-mediated signaling pathway, and that Nexrutine activates cyclin D1, which prevents the progression of prostate cancer . In this study, it was observed that P. indica leaf and root aqueous extracts inhibited GBM8401 malignant glioma cells and HeLa cervical carcinoma cell growth, and migration. We found that the crude aqueous extract P. indica root suppressed focus formation of GBM8401 and HeLa cells.
The p53 tumor-suppressor gene does not function properly in most human cancers . In brain cancers, p53 can be inactivated through amino acid-changing mutation in the DNA-binding domain and/or deletion of the p14ARF gene, and in cervical cancers, p53 is inactivated through viral infection [29, 30]. Phosphorylation of p53 by kinases, caused by DNA damage, leads to p53 activation . Phosphorylation of p53 can also occur in response to oxidative stress through the platelet-derived growth factor β receptor (PDGFβ)-mediated ataxia telangiectasia mutated (ATM) kinase activation or direct ATM activation by oxidative stress [32, 33]. One of the first consequences of p53 activation is cell cycle arrest through the p53-dependent expression of p21WAF1/CIP1, an inhibitor of cyclin-dependent kinases (CDKs) . Upregulation of p53 and p21 were found to be induced by lipid peroxidation in previous studies: lipid peroxidation increase was associated with p53 mRNA increase in a rat model , lipid peroxidation product from increased ferrous iron level in lysosomal compartment triggered upregulation of p53 , lipid peroxidation product sensitizes cells to UV-induced killing by inhibiting nucleotide excision repair and forming a peroxide-DNA adduct at codon 249 of the p53 gene , and that hydrogen peroxide-induced lipid peroxide production increased p21 expression . In the present study, it was observed that P. indica root crude aqueous extracts caused an increase in membrane lipid oxidation, and induced phosphorylated-p53 and p21expression in GBM8401 and HeLa cells.
The AKT/PKB (protein kinase B) kinases play important roles in signaling pathways that regulate cellular processes controlling cell proliferation, survival, and genome stability . Hyperactivation of the AKT pathway was implicated in many types of human cancer and dominantly inherited cancer syndrome. AKT phosphorylates and inactivates the pro-apoptotic factors BAD and procaspase-9 . In a pro-cell cycle progression mechanism involving p53, AKT promotes the phosphorylation and translocation of Mdm2 into the nucleus, where it downregulates p53, which antagonizes p53-mediated cell cycle checkpoints . AKT directly antagonizes the function of the cell cycle inhibitors p21WAF1 and p27Kip1 by phosphorylating a site located near the nuclear localization signal to induce cytoplasmic retention of these cell cycle inhibitors . Some investigations have shown elevated AKT activity to be highly prevalent in high grade, late stage and/or metastatic tumors, and several reports have linked AKT activation with reduced patient survival or tumor radio-resistance [42, 43]. In the present study, P. indica root crude aqueous extract treatment lowered the expression of activated phosphorylated-AKT, without affecting the expression of non-phosphorylated AKT, and induced the expression of phosphorylated-p53 and p21 in HeLa cells. Therefore, the pro-apoptotic and anti-proliferation properties of the crude aqueous extract of P. indica root might be attributed to its induction of phosphorylated-p53 and p21 through the downregulation of activated phosphorylated-AKT, which causes cell cycle arrest and initiation of apoptosis leading to cancer cell death.
The active components in crude aqueous extracts of P. indica root may be good candidates for further investigation into the search for effective anti-cancer and synergistic drugs. It is also important to note that aqueous extracts of herbal substance was previously found to be less toxic than ethanol extracts of herbal material; the LD50 of aqueous and ethanol extracts were 12.30 g/kg and 6.15 g/kg, respectively . We found that P. indica leaf and root crude aqueous extracts possess pro-oxidant, anti-proliferation, and anti-migration properties in GBM8401 malignant glioma cells and HeLa cervical carcinoma cells, and that P. indica root crude aqueous extract inhibited focus formation of these cancer cells. We also found that phosphorylated-p53 and p21 are induced in GBM8401 and HeLa cells after P. indica root crude aqueous extracts treatments. As keenly pointed out by a review, the challenge in CAM is to avoid contaminated products and those that may interact with prescription pharmaceuticals . Further examination into the underlying anti-cancer mechanism and pharmacodynamic and pharmacokinetic interactions with current cancer drugs should be carried out to ensure effective clinical application and usage of P. indica leaf or root crude aqueous extract.
In conclusion, the results of this study suggest that P. indica crude aqueous extracts has a promising anti-proliferative and anti-migratory effect on GBM8401 malignant glioma cells and HeLa cervical carcinoma cells. In addition, it was found that P. indica crude aqueous extracts induced critical tumor suppressor molecules, phosphorylated-p53 and p21, for cell cycle arrest and apoptosis, and downregulated an important survival signaling molecule, phosphorylated-AKT. Further investigations are needed to determine the entire anti-cancer molecular mechanism of P. indica aqueous extracts.
We are grateful to Dr. Tse-Min Lee for helpful comments on determination of lipid peroxidation. The authors are grateful for the experimental assistance of the flow cytometry experiment by Joshua Cho and E-Faan Chen and the grow curves, migration assay and part of the Western blotting by Shu-Chuan Tsao. This work is partially supported by "Aim for the Top University Plan" of the National Sun Yat-sen University (to C.L.C), and NSYSU-KMU Joint Research Project #NSYSUKMU 101–02 (to C.L.C. & C.N.T.) Taiwan.
- Munoz N, Bosch FX, de Sanjose S, Herrero R, Castellsague X, Shah KV, Snijders PJ, Meijer CJ: Epidemiologic classification of human papillomavirus types associated with cervical cancer. N Engl J Med. 2003, 348 (6): 518-527. 10.1056/NEJMoa021641.View ArticlePubMedGoogle Scholar
- Wrensch M, Minn Y, Chew T, Bondy M, Berger MS: Epidemiology of primary brain tumors: current concepts and review of the literature. Neuro Oncol. 2002, 4 (4): 278-299.PubMedPubMed CentralGoogle Scholar
- Smith RR, Malmgren RA: Cancer-cell wound seeding in surgery: a review. CA Cancer J Clin. 1964, 14: 90-103. 10.3322/canjclin.14.3.90. PASSIMView ArticlePubMedGoogle Scholar
- Timmerman RD, Bizekis CS, Pass HI, Fong Y, Dupuy DE, Dawson LA, Lu D: Local surgical, ablative, and radiation treatment of metastases. CA Cancer J Clin. 2009, 59 (3): 145-170. 10.3322/caac.20013.View ArticlePubMedGoogle Scholar
- Van Meir EG, Hadjipanayis CG, Norden AD, Shu HK, Wen PY, Olson JJ: Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma. CA Cancer J Clin. 2010, 60 (3): 166-193. 10.3322/caac.20069.View ArticlePubMedPubMed CentralGoogle Scholar
- Cassileth BR: Evaluating complementary and alternative therapies for cancer patients. CA Cancer J Clin. 1999, 49 (6): 362-375. 10.3322/canjclin.49.6.362.View ArticlePubMedGoogle Scholar
- Sparreboom A, Cox MC, Acharya MR, Figg WD: Herbal remedies in the united states: potential adverse interactions with anticancer agents. J Clin Oncol. 2004, 22 (12): 2489-2503. 10.1200/JCO.2004.08.182.View ArticlePubMedGoogle Scholar
- Bardia A, Barton DL, Prokop LJ, Bauer BA, Moynihan TJ: Efficacy of complementary and alternative medicine therapies in relieving cancer pain: a systematic review. J Clin Oncol. 2006, 24 (34): 5457-5464. 10.1200/JCO.2006.08.3725.View ArticlePubMedGoogle Scholar
- Boon H, Stewart M, Kennard MA, Gray R, Sawka C, Brown JB, McWilliam C, Gavin A, Baron RA, Aaron D: Use of complementary/alternative medicine by breast cancer survivors in ontario: prevalence and perceptions. J Clin Oncol. 2000, 18 (13): 2515-2521.PubMedGoogle Scholar
- McCulloch M, See C, Shu XJ, Broffman M, Kramer A, Fan WY, Gao J, Lieb W, Shieh K, Colford JM: Astragalus-based chinese herbs and platinum-based chemotherapy for advanced non-small-cell lung cancer: meta-analysis of randomized trials. J Clin Oncol. 2006, 24 (3): 419-430. 10.1200/JCO.2005.03.6392.View ArticlePubMedGoogle Scholar
- Sen T, Dhara AK, Bhattacharjee S, Pal S, Nag chaudhuri AK: Antioxidant activity of the methanol fraction of pluchea indica root extract. Phytother Res. 2002, 16 (4): 331-335. 10.1002/ptr.892.View ArticlePubMedGoogle Scholar
- Sen T, Nag chaudhuri AK: Antiinflammatory evaluation of a pluchea indica root extract. J Ethnopharmacol. 1991, 33 (1–2): 135-141.View ArticlePubMedGoogle Scholar
- Gomes A, Saha A, Chatterjee I, Chakravarty AK: Viper and cobra venom neutralization by beta-sitosterol and stigmasterol isolated from the root extract of pluchea indica less. (Asteraceae). Phytomedicine. 2007, 14 (9): 637-643. 10.1016/j.phymed.2006.12.020.View ArticlePubMedGoogle Scholar
- Sen T, Ghosh TK, Chaudhuri AK: Studies on the mechanism of anti-inflammatory and anti-ulcer activity of pluchea indica–probable involvement of 5-lipooxygenase pathway. Life Sci. 1993, 52 (8): 737-743. 10.1016/0024-3205(93)90236-V.View ArticlePubMedGoogle Scholar
- Mohamad S, Zin NM, Wahab HA, Ibrahim P, Sulaiman SF, Zahariluddin AS, Noor SS: Antituberculosis potential of some ethnobotanically selected malaysian plants. J Ethnopharmacol. 2011, 133 (3): 1021-1026. 10.1016/j.jep.2010.11.037.View ArticlePubMedGoogle Scholar
- Li XK, Motwani M, Tong W, Bornmann W, Schwartz GK: Huanglian, a chinese herbal extract, inhibits cell growth by suppressing the expression of cyclin B1 and inhibiting CDC2 kinase activity in human cancer cells. Mol Pharmacol. 2000, 58 (6): 1287-1293.PubMedGoogle Scholar
- Harborne JB: Phytochemical methods: a guide to modern techniques of plant analysis. 1998, London, New York: Chapman and Hall, 3Google Scholar
- Butler LG, Price ML, Brotherton JE: Vanillin assay for proanthocyanidins (condensed tannins): modification of the solvent for estimation of the degree of polymerization. J Agric Food Chem. 1982, 49 (3): 1169-1174.Google Scholar
- Janero DR: Malondialdehyde and thiobarbituric acid-reactivity as diagnostic indices of lipid peroxidation and peroxidative tissue injury. Free Radic Biol Med. 1990, 9 (6): 515-540. 10.1016/0891-5849(90)90131-2.View ArticlePubMedGoogle Scholar
- West KA, Zhang H, Brown MC, Nikolopoulos SN, Riedy MC, Horwitz AF, Turner CE: The LD4 motif of paxillin regulates cell spreading and motility through an interaction with paxillin kinase linker (PKL). J Cell Biol. 2001, 154 (1): 161-176. 10.1083/jcb.200101039.View ArticlePubMedPubMed CentralGoogle Scholar
- Wink M, Ashour ML, El-Readi MZ: Secondary metabolites from plants inhibiting ABC transporters and reversing resistance of cancer cells and microbes to cytotoxic and antimicrobial agents. Front Microbiol. 2012, 3: 130-View ArticlePubMedPubMed CentralGoogle Scholar
- Zamora-Ros R, Agudo A, Lujan-Barroso L, Romieu I, Ferrari P, Knaze V, Bueno-de-Mesquita HB, Leenders M, Travis RC, Navarro C: Dietary flavonoid and lignan intake and gastric adenocarcinoma risk in the european prospective investigation into cancer and nutrition (EPIC) study. Am J Clin Nutr. 2012, 96 (6): 1398-1408. 10.3945/ajcn.112.037358.View ArticlePubMedGoogle Scholar
- Law PC, Auyeung KK, Chan LY, Ko JK: Astragalus saponins downregulate vascular endothelial growth factor under cobalt chloride-stimulated hypoxia in colon cancer cells. BMC Complement Altern Med. 2012, 12: 160-10.1186/1472-6882-12-160.View ArticlePubMedPubMed CentralGoogle Scholar
- Prasad R, Vaid M, Katiyar SK: Grape proanthocyanidin inhibit pancreatic cancer cell growth in vitro and in vivo through induction of apoptosis and by targeting the PI3K/Akt pathway. PLoS One. 2012, 7 (8): e43064-10.1371/journal.pone.0043064.View ArticlePubMedPubMed CentralGoogle Scholar
- Ghavami G, Sardari S, Ali Shokrgozar M: Cheminformatics-based selection and synergism of herbal extracts with anticancer agents on drug resistance tumor cells-ACHN and A2780/CP cell lines. Comput Biol Med. 2011, 41 (8): 665-674. 10.1016/j.compbiomed.2011.06.002.View ArticlePubMedGoogle Scholar
- Tsai NM, Chen YL, Lee CC, Lin PC, Cheng YL, Chang WL, Lin SZ, Harn HJ: The natural compound n-butylidenephthalide derived from angelica sinensis inhibits malignant brain tumor growth in vitro and in vivo. J Neurochem. 2006, 99 (4): 1251-1262. 10.1111/j.1471-4159.2006.04151.x.View ArticlePubMedPubMed CentralGoogle Scholar
- Kumar AP, Bhaskaran S, Ganapathy M, Crosby K, Davis MD, Kochunov P, Schoolfield J, Yeh IT, Troyer DA, Ghosh R: Akt/cAMP-responsive element binding protein/cyclin D1 network: a novel target for prostate cancer inhibition in transgenic adenocarcinoma of mouse prostate model mediated by nexrutine, a phellodendron amurense bark extract. Clin Cancer Res. 2007, 13 (9): 2784-2794. 10.1158/1078-0432.CCR-06-2974.View ArticlePubMedPubMed CentralGoogle Scholar
- Vousden KH, Prives C: Blinded by the light: the growing complexity of p53. Cell. 2009, 137 (3): 413-431. 10.1016/j.cell.2009.04.037.View ArticlePubMedGoogle Scholar
- Vogelstein B, Lane D, Levine AJ: Surfing the p53 network. Nature. 2000, 408 (6810): 307-310. 10.1038/35042675.View ArticlePubMedGoogle Scholar
- Chen TP, Chen CM, Chang HW, Wang JS, Chang WC, Hsu SI, Cho CL: Increased expression of SKP2 and phospho-MAPK/ERK1/2 and decreased expression of p27 during tumor progression of cervical neoplasms. Gynecol Oncol. 2007, 104 (3): 516-523. 10.1016/j.ygyno.2006.09.015.View ArticlePubMedGoogle Scholar
- Brady CA, Jiang D, Mello SS, Johnson TM, Jarvis LA, Kozak MM, Kenzelmann Broz D, Basak S, Park EJ, McLaughlin ME: Distinct p53 transcriptional programs dictate acute DNA-damage responses and tumor suppression. Cell. 2011, 145 (4): 571-583. 10.1016/j.cell.2011.03.035.View ArticlePubMedPubMed CentralGoogle Scholar
- Chen K, Albano A, Ho A, Keaney JF: Activation of p53 by oxidative stress involves platelet-derived growth factor-beta receptor-mediated ataxia telangiectasia mutated (ATM) kinase activation. J Biol Chem. 2003, 278 (41): 39527-39533. 10.1074/jbc.M304423200.View ArticlePubMedGoogle Scholar
- Guo Z, Kozlov S, Lavin MF, Person MD, Paull TT: ATM activation by oxidative stress. Science. 2010, 330 (6003): 517-521. 10.1126/science.1192912.View ArticlePubMedGoogle Scholar
- Seoane J, Le HV, Massague J: Myc suppression of the p21(Cip1) Cdk inhibitor influences the outcome of the p53 response to DNA damage. Nature. 2002, 419 (6908): 729-734. 10.1038/nature01119.View ArticlePubMedGoogle Scholar
- Koz ST, Etem EO, Baydas G, Yuce H, Ozercan HI, Kuloglu T, Koz S, Etem A, Demir N: Effects of resveratrol on blood homocysteine level, on homocysteine induced oxidative stress, apoptosis and cognitive dysfunctions in rats. Brain Res. 2012, 1484: 29-38.View ArticlePubMedGoogle Scholar
- Bresgen N, Jaksch H, Lacher H, Ohlenschlager I, Uchida K, Eckl PM: Iron-mediated oxidative stress plays an essential role in ferritin-induced cell death. Free Radic Biol Med. 2010, 48 (10): 1347-1357. 10.1016/j.freeradbiomed.2010.02.019.View ArticlePubMedGoogle Scholar
- Feng Z, Hu W, Tang MS: Trans-4-hydroxy-2-nonenal inhibits nucleotide excision repair in human cells: a possible mechanism for lipid peroxidation-induced carcinogenesis. Proc Natl Acad Sci USA. 2004, 101 (23): 8598-8602. 10.1073/pnas.0402794101.View ArticlePubMedPubMed CentralGoogle Scholar
- Lee YJ, Lee JH, Han HJ: Extracellular adenosine triphosphate protects oxidative stress-induced increase of p21(WAF1/Cip1) and p27(Kip1) expression in primary cultured renal proximal tubule cells: role of PI3K and Akt signaling. J Cell Physiol. 2006, 209 (3): 802-810. 10.1002/jcp.20763.View ArticlePubMedGoogle Scholar
- Bellacosa A, Kumar CC, Di Cristofano A, Testa JR: Activation of AKT kinases in cancer: implications for therapeutic targeting. Adv Cancer Res. 2005, 94: 29-86.View ArticlePubMedGoogle Scholar
- Zhou BP, Hung MC: Novel targets of Akt, p21(cipl/WAF1), and MDM2. Semin Oncol. 2002, 29 (3 Suppl 11): 62-70. 10.1053/sonc.2002.34057.View ArticlePubMedGoogle Scholar
- Testa JR, Bellacosa A: AKT plays a central role in tumorigenesis. Proc Natl Acad Sci USA. 2001, 98 (20): 10983-10985. 10.1073/pnas.211430998.View ArticlePubMedPubMed CentralGoogle Scholar
- Tsao AS, McDonnell T, Lam S, Putnam JB, Bekele N, Hong WK, Kurie JM: Increased phospho-AKT (Ser(473)) expression in bronchial dysplasia: implications for lung cancer prevention studies. Cancer Epidemiol Biomarkers Prev. 2003, 12 (7): 660-664.PubMedGoogle Scholar
- Balsara BR, Pei J, Mitsuuchi Y, Page R, Klein-Szanto A, Wang H, Unger M, Testa JR: Frequent activation of AKT in non-small cell lung carcinomas and preneoplastic bronchial lesions. Carcinogenesis. 2004, 25 (11): 2053-2059. 10.1093/carcin/bgh226.View ArticlePubMedGoogle Scholar
- Frida L, Rakotonirina S, Rakotonirina A, Savineau JP: In vivo and in vitro effects of bidens pilosa L. (Asteraceae) leaf aqueous and ethanol extracts on primed-oestrogenized rat uterine muscle. Afr J Tradit Complement Altern Med. 2007, 5 (1): 79-91.PubMedPubMed CentralGoogle Scholar
- The pre-publication history for this paper can be accessed here:http://www.biomedcentral.com/1472-6882/12/265/prepub
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.